Hyperglycemia has an adverse prognostic impact in patients affected by glioblastoma [2,3] and high intracellular glucose increases resistance of glioblastoma cells to therapies targeting epidermal growth factor receptor, phosphoinositide 3-kinase and AKT [4]. This evidence concerns the gene EGFR and glioblastoma.